Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected ...

Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in ...

In March, she announced that her cancer was found after a planned abdominal surgery and that she'd need to undergo chemotherapy to prevent the cancer from recurring. In June, she shared that she ...

Title: INX-315, an oral, potent and selective CDK2 inhibitor in patients with CDK4/6 inhibitor resistant ER+/HER2- breast cancer or CCNE1 amplified solid tumors: phase 1 monotherapy dose escalation ...

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial ...

A powerful, three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines: Basel Saturday, October 26, 2024, 14:00 Hrs [IST] This month, the NCCN ...

The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is ...

Notably, tumor regressions were observed in small-cell lung cancer (SCLC), non-small-cell ... CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that ...